Thus, our data could stratify nonmetastatic CRC patients with different survival risks, i.e., CEA-low (<4.9 ng/mL), CEA-medium (4.9–27.2 ng/mL), and CEA-high (>27.2 ng/mL) groups. This evidence concerns the gene CEACAM5 and colorectal carcinoma.